Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients

American Journal of Gastroenterology

Volumn 105, Issue 9, 2010, Pages 1970-1977

  Khattab, Mahmoud ^a   Eslam, Mohammed ^a   Sharwae, Mohammed Ahmed ^a   Shatat, Mohammed ^a   Ali, Ahmed ^a   Hamdy, Lamia ^a  

^a MINIA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; DRUG DOSE REDUCTION; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; LIVER FIBROSIS; LIVER FUNCTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE; VIRUS HEPATITIS; VIRUS LOAD; BODY MASS; CHI SQUARE DISTRIBUTION; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; NONPARAMETRIC TEST; PROSPECTIVE STUDY; RISK; STATISTICAL MODEL; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INTERFERON ALFA-2B; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; INTERFERON-ALPHA; RECOMBINANT PROTEINS;

EID: 77956343048     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.110     Document Type: Article

References (27)

1. World Health Organization. Hepatitis C. Fact Sheet Number 164, Revised October 2000. (http://www.who.int/mediacentre/factssheets/fs164len) Accessed 6 March 2009
2. Koshy A, Marcellin P, Martinot M et al. Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis. Liver 2000; 20: 335-339
3. Zylberberg H, Chaix ML, Brechot C. Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha. Ann Intern Med 2000; 132: 845-846
4. Kamal SM, Madwar MA, Peters T et al. Interferon therapy in patients with chronic hepatitis C and schistosomiasis. J Hepatol 2000; 32: 172-174
5. Kamal SM, Nasser IA. Hepatitis C genotype 4: what we know and what we don ' t yet know. Hepatology 2008; 47: 1371-1383
6. Legrand-Abravanel F, Nicot F, Boulestin A et al. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J Med Virol 2005; 77: 66-69
7. Kamal SM, El Kamary SS, Shardell MD et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007; 46: 1732-1740
8. Romero-Gomez M, Del Mar Viloria M, Andrade RJ et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-641
9. D 'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005; 100: 1509-1515
10. Lo Iacono O, Venezia G, Petta S et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007; 25: 1181-1191
11. Moucari R, Asselah T, Cazals-Hatem D et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416-423
12. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293
13. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27 (Suppl 1): s5-10
14. Bonora E, Targher G, Alberiche M et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63
15. Strader DB, Wright T, Th omas DL et al. Diagnosis, management and treatment of Hepatitis C. Hepatology 2004; 39: 1147-1171
16. Ferenci P, Fried MW, Shiffman ML et al. Predicting sustained virologic responses in chronic hepatitis C patients treated with peginterferon alpha-2a ribavirin. J Hepatol 2005; 43: 425-433
17. Carlsson T, Reichard O, Norkrans G et al. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferonalpha 2a and ribavirin according to virologic response. J Viral Hepatol 2005; 12: 473-480
18. Nasta P, Gatti F, Puoti M et al. Insulin resistance impairs rapid virological response in HIV/hepatitis C virus coinfected patients on peginterferonalpha-2a. AIDS 2008; 22: 857-861
19. Poustchi H, Negro F, Hui J et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008; 48: 28-34
20. Walsh MJ, Jonsson JR, Richardson MM et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55: 529-535
21. Bernsmeier C, Duong FH, Christen V et al. Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. J Hepatol 2008; 49: 429-440
22. Knobler H, Zhornicky T, Sandler A et al. Tumor necrosis factor-alphainduced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol 2003; 98: 2751-2756
23. Larrea E, Garcia N, Qian C et al. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996; 23: 210-217
24. Koivisto VA, Pelkonen R, Cantell K. effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 1989; 38: 641-647
25. Imano E, Kanda T, Ishigami Y et al. Interferon induces insulin resistance in patients with chronic active hepatitis C. J Hepatol 1998; 28: 189-193
26. Khattab MA. Targeting host factors: a novel rationale for the management of hepatitis C virus. World J Gastroenterol 2009; 15: 3471-3479
27. Khattab MA, Abdel-fattah ME, Abdelaleem A et al. Pioglitazone improves virological response to peginterferon-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int 2010; 30: 447-455.